ArticleHeart (British Cardiac Society)2002
Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.
Article in Heart (British Cardiac Society), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 134 citations in OpenAlex.
- Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Trial
- Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy.World journal of gastroenterology · 2006Trial
- Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study.The American journal of medicine · 2004Trial
- Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair.ESC heart failure · 2025Article
- Artificial Intelligence-Enabled Electrocardiography Detects B-Type Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Application of high-performance magnetic nanobeads to biological sensing devices.Analytical and bioanalytical chemistry · 2019Review
- NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department.Clinical cardiology · 2018Article
- Intervention for Varicose Veins of Lower Extremities Lowers the Brain Natriuretic Peptide Values in Varicose Vein Patients.Annals of vascular diseases · 2017Article
- Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure.Journal of clinical medicine research · 2016Article
- Prevalence of atrial fibrillation in the Malaysian communities.Heart Asia · 2016Article
- Article
- Article
- Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution.Cardiovascular diabetology · 2012Article
- Review
- N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population.Korean circulation journal · 2010Article
- Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure.Journal of endocrinological investigation · 2010Article
- The relationship between heart rate recovery and brain natruretic Peptide in patients with chest discomfort: a study for relationship between heart rate recovery and pre-exercise, post-exercise levels of brain natruretic Peptide in patients with normal systolic function and chest discomfort.Korean circulation journal · 2010Article
- Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.Current cardiovascular risk reports · 2010Article
- High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia.World journal of gastroenterology · 2009Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConflict exists regarding the usefulness of measuring plasma B type natriuretic peptide (BNP) concentrations for identifying impaired left ventricular (LV) systolic function during mass screening. Various cardiac abnormalities, regardless of degree of LV dysfunction, are prone to carry a high risk of cardiovascular events.
objectiveTo examine the validity of plasma BNP measurement for detection of various cardiac abnormalities in a population with a low prevalence of coronary heart disease and LV systolic dysfunction. DESIGN AND
settingParticipants in this cross sectional study attended a health screening programme in Iwate, northern Japan. Plasma BNP concentrations were determined in 1098 consecutive subjects (mean age 56 years) by direct radioimmunoassay. All subjects underwent multiphasic health checkups including physical examination, ECG, chest radiography, and transthoracic echocardiography.
resultsConventional diagnostic methods showed 39 subjects to have a wide range of cardiac abnormalities: lone atrial fibrillation or flutter in 11; previous myocardial infarction in seven; valvar heart disease in seven; hypertensive heart disease in six; cardiomyopathy in six; atrial septal defect in one; and cor pulmonale in one. No subjects had a low LV ejection fraction (< 40%). To assess the utility of plasma BNP measurement for identification of such patients, receiver operating characteristic analysis was performed. The optimal threshold for identification was a BNP concentration of 50 pg/ml with sensitivity of 89.7% and specificity of 95.7%. The area under the receiver operating characteristic curve was 0.970. The positive and negative predictive values at the cutoff level were 44.3% and 99.6%, respectively.
conclusionMeasurement of plasma BNP concentration is a very efficient and cost effective mass screening technique for identifying patients with various cardiac abnormalities regardless of aetiology and degree of LV systolic dysfunction that can potentially develop into obvious heart failure and carry a high risk of a cardiovascular event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.